Santhera's idebenone hits top-line in Phase III DMD trial

Santhera Pharmaceticals' Phase III DELIOS study of idebenone in Duchenne muscular dystrophy (DMD) has reached its primary endpoint of delaying the loss of respiratory function compared with placebo, the company says. It is planning to talk to US and EU regulators about the best way forward for the product on the back of the data.